Copyright
©The Author(s) 2022.
World J Hepatol. Apr 27, 2022; 14(4): 766-777
Published online Apr 27, 2022. doi: 10.4254/wjh.v14.i4.766
Published online Apr 27, 2022. doi: 10.4254/wjh.v14.i4.766
Figure 1 Illustrates a flow diagram for study inclusion.
STEMI: ST-elevation myocardial infarction-related cardiogenic shock.
Figure 2 This bar chart provides a direct visual comparison of the baseline comorbidities between the two groups.
AIDS: Acquired immune deficiency syndrome; CKD: Chronic kidney disease; COPD: Chronic obstructive pulmonary disease; HIV: Human immunodeficiency virus; HLD: Hypomyelinating leukodystrophies; CHF: Chronic heart failure; PVD: Peripheral vascular disease.
Figure 3 This Forrest plot reflects the mortality odds ratios for each intervention for cirrhotic patients with ST-elevation myocardial infarction-related cardiogenic shock.
SRCS: ST-elevation myocardial infarction-related cardiogenic shock; PCI: Percutaneous coronary intervention.
- Citation: Dar SH, Rahim M, Hosseini DK, Sarfraz K. Impact of liver cirrhosis on ST-elevation myocardial infarction related shock and interventional management, a nationwide analysis. World J Hepatol 2022; 14(4): 766-777
- URL: https://www.wjgnet.com/1948-5182/full/v14/i4/766.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i4.766